Maria Feldt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maria Feldt has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Signe Borgquist
Department of Oncology, Aarhus University Hospital/Aarhus University, Aarhus, Denmark
2 shared publications Ann H Rosendahl
Lund University, Lund, Sweden
1 shared publicationAnn H. Rosendahl
Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden
1 shared publicationBarbara Lettiero
Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden
1 shared publication- Deirdre Cronin-Fenton
Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
1 shared publication - Dorthe Grabau
Department of Pathology, Skåne University Hospital, Lund, Sweden
1 shared publication
Latest Publications
- Open Access
- 15 February 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (4_Suppleme) , P4-07
Abstract P4-07-06: Circulating lipids and breast cancer survival in the Malmö diet and cancer study
Rationale: Overweight and obesity are associated with inferior prognosis in breast cancer. The explanation is considered multifactorial, and dyslipidemia may be a contributing factor. The purpose of this study was to examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Patients and methods: Circulating lipid levels were measured in the blood sampled upon enrollment in the female MDCS cohort (N=17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991-2014. The follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or five years of follow-up. We estimated the incidence rates of recurrence at five years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B). Results: We enrolled 850 eligible patients. During the five years of follow up, 90 invasive recurrences with over 3,807 person-years occurred. In multivariable analyses, high levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR= 2.30 [95% CI: 1.13-4.68]). However, high levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR= 1.23 [95%CI: 0.68-2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR= 1.34 [95%CI: 0.70-2.58]) or all-cause mortality (tertile 3 vs. 1, HR=1.12 [95%CI: 0.61-2.05]). Conclusion: High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcome. These results warrant further investigation into the importance of lipid-regulation in breast cancer patients. Citation Format: Sixten Harborg, Thomas P Ahern, Maria Feldt, Ann H Rosendahl, Deirdre Cronin-Fenton, Olle Melander, Signe Borgquist. Circulating lipids and breast cancer survival in the Malmö diet and cancer study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-06.
- 15 February 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (4_Suppleme) , P4-07
Open AccessAbstract P4-07-06: Circulating lipids and breast cancer survival in the Malmö diet and cancer study
Rationale: Overweight and obesity are associated with inferior prognosis in breast cancer. The explanation is considered multifactorial, and dyslipidemia may be a contributing factor. The purpose of this study was to examine the association between circulating lipids and breast cancer outcomes in patients enrolled in the Malmö Diet and Cancer Study (MDCS). Patients and methods: Circulating lipid levels were measured in the blood sampled upon enrollment in the female MDCS cohort (N=17,035). We identified all MDCS participants with incident invasive breast cancer diagnosed between 1991-2014. The follow-up time began at breast cancer diagnosis and continued until the first event of breast cancer recurrence, death, emigration, or five years of follow-up. We estimated the incidence rates of recurrence at five years and fit Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI) of breast cancer recurrence as well as all-cause mortality according to cohort-specific tertiles of apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B). Results: We enrolled 850 eligible patients. During the five years of follow up, 90 invasive recurrences with over 3,807 person-years occurred. In multivariable analyses, high levels of Apo B were associated with an increased rate of recurrence (tertile 3 vs. 1, HR= 2.30 [95% CI: 1.13-4.68]). However, high levels of Apo B were not associated with all-cause mortality (tertile 3 vs. 1, HR= 1.23 [95%CI: 0.68-2.25]). We observed no associations between levels of Apo A-1 and recurrence (tertile 3 vs. 1, HR= 1.34 [95%CI: 0.70-2.58]) or all-cause mortality (tertile 3 vs. 1, HR=1.12 [95%CI: 0.61-2.05]). Conclusion: High pre-diagnostic levels of Apo B were associated with an increased risk of recurrence among breast cancer patients. Circulating Apo A-1 was not associated with breast cancer outcome. These results warrant further investigation into the importance of lipid-regulation in breast cancer patients. Citation Format: Sixten Harborg, Thomas P Ahern, Maria Feldt, Ann H Rosendahl, Deirdre Cronin-Fenton, Olle Melander, Signe Borgquist. Circulating lipids and breast cancer survival in the Malmö diet and cancer study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-06.
- Open Access
- 23 November 2020
- Published by Springer Nature in Cancer & Metabolism
- Vol. 8 (1) , 1-16
The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial
Background: Deregulated lipid metabolism is common in cancer cells and the mevalonate pathway, which synthesizes cholesterol, is central in lipid metabolism. This study aimed to assess statin-induced changes of the intratumoral levels of cholesterol and the expression of the low-density lipoprotein receptor (LDLR) to enhance our understanding of the role of the mevalonate pathway in cancer cholesterol metabolism.Methods: This study is based on a phase II clinical trial designed as a window-of-opportunity trial including 50 breast cancer patients treated with 80 mg of atorvastatin/day for 2 weeks, between the time of diagnosis and breast surgery. Lipids were extracted from frozen tumor tissue sampled pre- and post-atorvastatin treatment. Intratumoral cholesterol levels were measured using a fluorometric quantitation assay. LDLR expression was evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tumor tissue. Paired blood samples pre- and post-atorvastatin were analyzed for circulating low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A1, and apolipoprotein B. In vitro experiments on MCF-7 breast cancer cells treated with atorvastatin were performed for comparison on the cellular level.Results: In the trial, 42 patients completed all study parts. From the paired tumor tissue samples, assessment of the cholesterol levels was achievable for 14 tumors, and for the LDLR expression in 24 tumors. Following atorvastatin treatment, the expression of LDLR was significantly increased (P= 0.004), while the intratumoral levels of total cholesterol remained stable. A positive association between intratumoral cholesterol levels and tumor proliferation measured by Ki-67 expression was found. In agreement with the clinical findings, results from in vitro experiments showed no significant changes of the intracellular cholesterol levels after atorvastatin treatment while increased expression of the LDLR was found, although not reaching statistical significance.Conclusions: This study shows an upregulation of LDLR and preserved intratumoral cholesterol levels in breast cancer patients treated with statins. Together with previous findings on the anti-proliferative effect of statins in breast cancer, the present data suggest a potential role for LDLR in the statin-induced regulation of breast cancer cell proliferation.Trial registration: The study has been registered at ClinicalTrials.gov (i.e., ID number:NCT00816244, NIH), December 30, 2008.
- 23 November 2020
- Published by Springer Nature in Cancer & Metabolism
- Vol. 8 (1) , 1-16
Open AccessThe effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial
Background: Deregulated lipid metabolism is common in cancer cells and the mevalonate pathway, which synthesizes cholesterol, is central in lipid metabolism. This study aimed to assess statin-induced changes of the intratumoral levels of cholesterol and the expression of the low-density lipoprotein receptor (LDLR) to enhance our understanding of the role of the mevalonate pathway in cancer cholesterol metabolism.Methods: This study is based on a phase II clinical trial designed as a window-of-opportunity trial including 50 breast cancer patients treated with 80 mg of atorvastatin/day for 2 weeks, between the time of diagnosis and breast surgery. Lipids were extracted from frozen tumor tissue sampled pre- and post-atorvastatin treatment. Intratumoral cholesterol levels were measured using a fluorometric quantitation assay. LDLR expression was evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tumor tissue. Paired blood samples pre- and post-atorvastatin were analyzed for circulating low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A1, and apolipoprotein B. In vitro experiments on MCF-7 breast cancer cells treated with atorvastatin were performed for comparison on the cellular level.Results: In the trial, 42 patients completed all study parts. From the paired tumor tissue samples, assessment of the cholesterol levels was achievable for 14 tumors, and for the LDLR expression in 24 tumors. Following atorvastatin treatment, the expression of LDLR was significantly increased (P= 0.004), while the intratumoral levels of total cholesterol remained stable. A positive association between intratumoral cholesterol levels and tumor proliferation measured by Ki-67 expression was found. In agreement with the clinical findings, results from in vitro experiments showed no significant changes of the intracellular cholesterol levels after atorvastatin treatment while increased expression of the LDLR was found, although not reaching statistical significance.Conclusions: This study shows an upregulation of LDLR and preserved intratumoral cholesterol levels in breast cancer patients treated with statins. Together with previous findings on the anti-proliferative effect of statins in breast cancer, the present data suggest a potential role for LDLR in the statin-induced regulation of breast cancer cell proliferation.Trial registration: The study has been registered at ClinicalTrials.gov (i.e., ID number:NCT00816244, NIH), December 30, 2008.
- Open Access
- 29 April 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 1-11
Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial
Cholesterol lowering statins have been demonstrated to exert anti-tumoral effects on breast cancer by decreasing proliferation as measured by Ki67. The biological mechanisms behind the anti-proliferative effects remain elusive. The aim of this study was to investigate potential statin-induced effects on the central cell cycle regulators cyclin D1 and p27. This phase II window-of-opportunity trial (Trial registration: ClinicalTrials.gov NCT00816244 , NIH) included 50 patients with primary invasive breast cancer. High-dose atorvastatin (80 mg/day) was prescribed to patients for two weeks prior to surgery. Paired paraffin embedded pre- and post-statin treatment tumor samples were analyzed using immunohistochemistry for the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and the cell cycle regulators cyclin D1 and p27. Corresponding frozen tumor sample pairs were analyzed for expression of the genes coding for cyclin D1 and p27, CCND1 and CDKN1B, respectively. Forty-two patients completed all study parts, and immunohistochemical evaluation of ER and PR was achievable in 30 tumor pairs, HER2 in 29 tumor pairs, cyclin D1 in 30 tumor pairs and p27 in 33 tumor pairs. The expression of ER, PR and HER2 did not change significantly following atorvastatin treatment. Cyclin D1 expression in terms of nuclear intensity was significantly decreased (P = 0.008) after statin treatment in paired tumor samples. The protein expression of the tumor suppressor p27, evaluated either as the fraction of stained tumor cells or as cytoplasmic intensity, increased significantly (P = 0.03 and P = 0.02, respectively). At the transcriptional level, no significant differences in mRNA expression were detected for cyclin D1 (CCND1) and p27 (CDKN1B). However, CCND1 expression was lower in tumors responding to atorvastatin treatment with a decrease in proliferation although not significantly (P = 0.08). We have previously reported statin-induced anti-proliferative effects in breast cancer. This study suggests that cell cycle regulatory effects may contribute to these anti-proliferative effects via cyclin D1 and p27.
- 29 April 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 1-11
Open AccessStatin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial
Cholesterol lowering statins have been demonstrated to exert anti-tumoral effects on breast cancer by decreasing proliferation as measured by Ki67. The biological mechanisms behind the anti-proliferative effects remain elusive. The aim of this study was to investigate potential statin-induced effects on the central cell cycle regulators cyclin D1 and p27. This phase II window-of-opportunity trial (Trial registration: ClinicalTrials.gov NCT00816244 , NIH) included 50 patients with primary invasive breast cancer. High-dose atorvastatin (80 mg/day) was prescribed to patients for two weeks prior to surgery. Paired paraffin embedded pre- and post-statin treatment tumor samples were analyzed using immunohistochemistry for the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and the cell cycle regulators cyclin D1 and p27. Corresponding frozen tumor sample pairs were analyzed for expression of the genes coding for cyclin D1 and p27, CCND1 and CDKN1B, respectively. Forty-two patients completed all study parts, and immunohistochemical evaluation of ER and PR was achievable in 30 tumor pairs, HER2 in 29 tumor pairs, cyclin D1 in 30 tumor pairs and p27 in 33 tumor pairs. The expression of ER, PR and HER2 did not change significantly following atorvastatin treatment. Cyclin D1 expression in terms of nuclear intensity was significantly decreased (P = 0.008) after statin treatment in paired tumor samples. The protein expression of the tumor suppressor p27, evaluated either as the fraction of stained tumor cells or as cytoplasmic intensity, increased significantly (P = 0.03 and P = 0.02, respectively). At the transcriptional level, no significant differences in mRNA expression were detected for cyclin D1 (CCND1) and p27 (CDKN1B). However, CCND1 expression was lower in tumors responding to atorvastatin treatment with a decrease in proliferation although not significantly (P = 0.08). We have previously reported statin-induced anti-proliferative effects in breast cancer. This study suggests that cell cycle regulatory effects may contribute to these anti-proliferative effects via cyclin D1 and p27.